Literature DB >> 28665299

Cytokine mediators of chronic graft-versus-host disease.

Kelli Pa MacDonald1, Bruce R Blazar2, Geoffrey R Hill3,4.   

Abstract

Substantial preclinical and clinical research into chronic graft-versus-host disease (cGVHD) has come to fruition in the last five years, generating a clear understanding of a complex cytokine-driven cellular network. cGVHD is mediated by naive T cells differentiating within IL-17-secreting T cell and follicular Th cell paradigms to generate IL-21 and IL-17A, which drive pathogenic germinal center (GC) B cell reactions and monocyte-macrophage differentiation, respectively. cGVHD pathogenesis includes thymic damage, impaired antigen presentation, and a failure in IL-2-dependent Treg homeostasis. Pathogenic GC B cell and macrophage reactions culminate in antibody formation and TGF-β secretion, respectively, leading to fibrosis. This new understanding permits the design of rational cytokine and intracellular signaling pathway-targeted therapeutics, reviewed herein.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28665299      PMCID: PMC5490762          DOI: 10.1172/JCI90593

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  170 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

2.  Sonic hedgehog signaling modulates activation of and cytokine production by human peripheral CD4+ T cells.

Authors:  Gareth A Stewart; Jacqueline A Lowrey; Sonia J Wakelin; Paul M Fitch; Susannah Lindey; Margaret J Dallman; Jonathan R Lamb; Sarah E M Howie
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

3.  The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation.

Authors:  Sayan Nandi; Solen Gokhan; Xu-Ming Dai; Suwen Wei; Grigori Enikolopov; Haishan Lin; Mark F Mehler; E Richard Stanley
Journal:  Dev Biol       Date:  2012-04-19       Impact factor: 3.582

Review 4.  The IL-17 differentiation pathway and its role in transplant outcome.

Authors:  Jonathan S Serody; Geoffrey R Hill
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

5.  Identification of the ligand-binding regions in the macrophage colony-stimulating factor receptor extracellular domain.

Authors:  Z E Wang; G M Myles; C S Brandt; M N Lioubin; L Rohrschneider
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

6.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

Authors:  Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

7.  The M-CSF receptor substrate and interacting protein FMIP is governed in its subcellular localization by protein kinase C-mediated phosphorylation, and thereby potentiates M-CSF-mediated differentiation.

Authors:  Annalisa Mancini; Alexandra Koch; Anthony D Whetton; Teruko Tamura
Journal:  Oncogene       Date:  2004-08-26       Impact factor: 9.867

8.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

Authors:  Paul J Martin; George W Counts; Frederick R Appelbaum; Stephanie J Lee; Jean E Sanders; H Joachim Deeg; Mary E D Flowers; Karen L Syrjala; John A Hansen; Rainer F Storb; Barry E Storer
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

9.  Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD).

Authors:  Baerbel Spies-Weisshart; Kristina Schilling; Frank Böhmer; Andreas Hochhaus; Herbert G Sayer; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2013-06-01       Impact factor: 4.553

Review 10.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

View more
  40 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Stacey Tannheimer; Amy J Johnson; Shuai Dong; Anne-Katrien Stark; Klaus Okkenhaug; Angela Panoskaltsis-Mortari; Peter T Sage; Arlene H Sharpe; Leo Luznik; Jerome Ritz; Robert J Soiffer; Corey S Cutler; John Koreth; Joseph H Antin; David B Miklos; Kelli P MacDonald; Geoffrey R Hill; Ivan Maillard; Jonathan S Serody; William J Murphy; David H Munn; Colby Feser; Michael Zaiken; Bart Vanhaesebroeck; Laurence A Turka; John C Byrd; Bruce R Blazar
Journal:  Am J Transplant       Date:  2019-03-19       Impact factor: 8.086

Review 3.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

4.  A critical role for donor-derived IL-22 in cutaneous chronic GVHD.

Authors:  Kate H Gartlan; Hemamalini Bommiasamy; Katelyn Paz; Andrew N Wilkinson; Mary Owen; Dawn K Reichenbach; Tatjana Banovic; Kimberly Wehner; Faith Buchanan; Antiopi Varelias; Rachel D Kuns; Karshing Chang; Yuri Fedoriw; Thomas Shea; James Coghill; Michael Zaiken; Maximilian W Plank; Paul S Foster; Andrew D Clouston; Bruce R Blazar; Jonathan S Serody; Geoffrey R Hill
Journal:  Am J Transplant       Date:  2017-10-24       Impact factor: 8.086

5.  IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation.

Authors:  Hao Li; Maria G Tsokos; Rhea Bhargava; Iannis E Adamopoulos; Hanni Menn-Josephy; Isaac E Stillman; Philip Rosenstiel; Jarrat Jordan; George C Tsokos
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

Review 6.  Formulary Drug Review: Belumosudil.

Authors:  Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2021-12-07

Review 7.  How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Authors:  Samantha M Jaglowski; Bruce R Blazar
Journal:  Blood Adv       Date:  2018-08-14

8.  Current Concepts and Advances in Graft-Versus-Host Disease Immunology.

Authors:  Geoffrey R Hill; Brian C Betts; Victor Tkachev; Leslie S Kean; Bruce R Blazar
Journal:  Annu Rev Immunol       Date:  2021-01-11       Impact factor: 28.527

Review 9.  Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease.

Authors:  Gérard Socié; Leslie S Kean; Robert Zeiser; Bruce R Blazar
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 19.456

10.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.